1. Af Bjerkén, S., Stenmark Persson, R., Barkander, A., Karalija, N., Pelegrina-Hidalgo, N., Gerhardt, G. A., Virel, A., & Strömberg, I. (2019). Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance. Neurochemistry International, 131, 104551.
2. Bertocci, B., Gill, G., & Da Prada, M. (1988). Prevention of the DSP-4-induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacogical Research Communications, 20, 131–132.
3. Booze, R. M., Hall, J. A., Cress, N. M., Miller, G. D., & Davis, J. N. (1988). DSP-4 treatment produces abnormal tyrosine hydroxylase immunoreactive fibers in rat hippocampus. Experimental Neurology, 101, 75–86.
4. Bortel, A., Nowak, P., & Brus, R. (2008a). Neonatal DSP-4 treatment modifies GABAergic neurotransmission in the prefrontal cortex of adult rats. Neurotoxicity Research, 13, 247–252.
5. Bortel, A., Slomian, L., Nitka, D., Swierszcz, M., Jaksz, M., Adamus-Sitkiewicz, B., Nowak, P., Josko, J., Kostrzewa, R. M., & Brus, R. (2008b). Neonatal N-(−2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) treatment modifies the vulnerability to phenobarbital- and ethanol-evoked sedative-hypnotic effects in adult rats. Pharmacological Reports, 60, 331–338.